Other cancer-associated sialyltrasferases include ST6GalNAc1 (which catalyses the cancer-associated sTn antigen) and is associated with metastasis [8,27,38,39,40,41,42,43], and ST6GALNAC2, which has been identified as a metastasis suppressor in breast cancer patients and could be used to stratify patients for treatment with galectin-3 inhibitors [44,45]. Here, EEF1A2 is linked to breast carcinoma.